These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 23047784)

  • 21. Postmarket surveillance. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2002 Jun; 67(109):38878-92. PubMed ID: 12053947
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adverse effects of drugs used to treat hematologic malignancies: surveillance efforts from the research on adverse drug events and reports project.
    Bennett CL; Tigue CC; Angelotta C; McKoy JM; Edwards BJ
    Semin Thromb Hemost; 2007 Jun; 33(4):365-72. PubMed ID: 17525894
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Feasibility of proactive medical device surveillance: the VA Clinical Assessment Reporting and Tracking (CART) program.
    Tsai TT; Box TL; Gethoffer H; Noonan G; Varosy PD; Maddox TM; Fihn SD; Gross TP; Jesse RL; Rumsfeld JS
    Med Care; 2013 Mar; 51(3 Suppl 1):S57-61. PubMed ID: 23407013
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Vaccine Safety Datalink: a model for monitoring immunization safety.
    Baggs J; Gee J; Lewis E; Fowler G; Benson P; Lieu T; Naleway A; Klein NP; Baxter R; Belongia E; Glanz J; Hambidge SJ; Jacobsen SJ; Jackson L; Nordin J; Weintraub E
    Pediatrics; 2011 May; 127 Suppl 1():S45-53. PubMed ID: 21502240
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Quality assessment of spontaneous triggered adverse event reports received by the Food and Drug Administration.
    Brajovic S; Piazza-Hepp T; Swartz L; Dal Pan G
    Pharmacoepidemiol Drug Saf; 2012 Jun; 21(6):565-70; discussion 571-2. PubMed ID: 22359404
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Medical product safety surveillance: how many databases to use?
    Maro JC; Brown JS; Kulldorff M
    Epidemiology; 2013 Sep; 24(5):692-9. PubMed ID: 23867812
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Postmarketing surveillance of corneal edema, Fuchs dystrophy, and amantadine use in the Veterans Health Administration.
    French DD; Margo CE
    Cornea; 2007 Oct; 26(9):1087-9. PubMed ID: 17893540
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The FDA's sentinel initiative--A comprehensive approach to medical product surveillance.
    Ball R; Robb M; Anderson SA; Dal Pan G
    Clin Pharmacol Ther; 2016 Mar; 99(3):265-8. PubMed ID: 26667601
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recalls. FDA, industry cooperate to protect consumers.
    Nordenberg T
    FDA Consum; 1995 Oct; 29(8):24-7. PubMed ID: 10151838
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improving product safety through data mining.
    FDA Consum; 2003; 37(4):5. PubMed ID: 12971330
    [No Abstract]   [Full Text] [Related]  

  • 31. Contract medical care; non-federal hospital payment rates--DVA and HHS. Final regulations.
    Fed Regist; 1990 Oct; 55(206):42848-53. PubMed ID: 10107908
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Automated support for pharmacovigilance: a proposed system.
    Bright RA; Nelson RC
    Pharmacoepidemiol Drug Saf; 2002 Mar; 11(2):121-5. PubMed ID: 11998536
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of databases in drug postmarketing surveillance.
    Rodriguez EM; Staffa JA; Graham DJ
    Pharmacoepidemiol Drug Saf; 2001; 10(5):407-10. PubMed ID: 11802586
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The London low emission zone baseline study.
    Kelly F; Armstrong B; Atkinson R; Anderson HR; Barratt B; Beevers S; Cook D; Green D; Derwent D; Mudway I; Wilkinson P;
    Res Rep Health Eff Inst; 2011 Nov; (163):3-79. PubMed ID: 22315924
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MedWatch. On lookout for medical product problems.
    Ropp KL
    FDA Consum; 1993 Nov; 27(9):14-7. PubMed ID: 10130376
    [No Abstract]   [Full Text] [Related]  

  • 36. Drug-safety pilot makes the grade.
    Ledford H
    Nature; 2014 Sep; 513(7519):472. PubMed ID: 25254456
    [No Abstract]   [Full Text] [Related]  

  • 37. Using high-dimensional propensity scores to automate confounding control in a distributed medical product safety surveillance system.
    Rassen JA; Schneeweiss S
    Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():41-9. PubMed ID: 22262592
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MedWatch: the FDA medical products reporting program.
    Rheinstein PH
    Am Fam Physician; 1993 Sep; 48(4):636-8. PubMed ID: 8379493
    [No Abstract]   [Full Text] [Related]  

  • 39. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.
    Wysowski DK; Swartz L
    Arch Intern Med; 2005 Jun; 165(12):1363-9. PubMed ID: 15983284
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety in numbers--monitoring risk in approved drugs.
    Okie S
    N Engl J Med; 2005 Mar; 352(12):1173-6. PubMed ID: 15788493
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.